Our results revealed that the group with high expression of LAPTM4A had a tendency to have a high TIDE score, implying that overexpression of LAPTM4A may reduce the effectiveness of immunotherapy in glioma patients while lowering LAPTM4A expression may improve the response rate to immunotherapy in patients. Here, LAPTM4A is linked to central nervous system cancer.